Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 5/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | EED | O75530 | 2/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300739 | 0.85 | CNR1 (0.45) | MAPK1NAMPT | |
| SCHEMBL186206 | 0.85 | SLC6A7 (0.44) | MAPK1KDM4EGRIN2BNAMPT | |
| SCHEMBL2175353 | 0.84 | MAPK1 (0.35) | MAPK1CDK9CCNT1JAK1EED | |
| SCHEMBL2179368 | 0.84 | EED (0.37) | MAPK1CDK9CCNT1JAK1EED | |
| SCHEMBL186594 | 0.82 | MEN1 (0.40) | MAPK1CDK9CCNT1GRIN2BNAMPT | |
| SCHEMBL2179315 | 0.81 | MAPT (0.45) | KDM4EALOX15 | |
| SCHEMBL2176291 | 0.81 | CCNT1 (0.36) | PARP1MAPK1CDK9CCNT1JAK1 | |
| SCHEMBL2176283 | 0.81 | SLC27A1 (0.38) | PARP1MAPK1CDK9CCNT1JAK1 | |
| SCHEMBL185941 | 0.80 | TRPV1 (0.40) | PARP1MAPK1GRIN2BNAMPT | |
| SCHEMBL186244 | 0.80 | MAPK1 (0.39) | MAPK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | claimed |
| EP-2297148-B8 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-03-28 | — | — | EP | claimed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | claimed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2297148-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | Sanofi-Aventis (FR) | 2011-03-23 | — | — | EP | claimed |
| WO-2009150388-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | claimed |
| US-8519143-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2012-09-13 | — | — | US | disclosed |
| US-8193190-B2 | Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | SANOFI-AVENTIS (FR) | 2012-06-05 | — | — | US | disclosed |
| EP-2297148-B8 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2297148-B1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2297148-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | Sanofi-Aventis (FR) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009150388-A1 | NOVEL DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALCANONE AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144116-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | PARP1 590/4885MAPK1 981/4885CDK9 2430/4885 |
| US-20120232280-A1 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS | NGF, NTRK2, NTRK3 | PARP1 590/4885MAPK1 981/4885CDK9 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.